Skip to content

Science & Innovation Theaters

AMCP invites you to join us for Science & Innovation Theater presentations held during Exposition hours in Exhibit Hall E at the George R. Brown Convention Center. AMCP’s Science & Innovation Theaters provide a structured focus for participants to gain information on specific products, therapeutic areas and/or disease states in presentations provided by company designated presenters. All theaters take place in the Exposition and are scheduled for Wednesday evening, April 22nd, Thursday lunch time, April 23rd and Friday morning, Aril  24th.  Two theaters are located in the back of the Exposition and are labeled Theater 1 and Theater 2.

AMCP Science & Innovation Theaters with a PIE logo include preapproval information exchange information.  Subject to federal laws and regulations, attendance at these sessions is restricted to payors, formulary committee, or other similar entity representatives with knowledge and expertise in the area of health care economic analysis, carrying out responsibilities for the selection of drugs for coverage or reimbursement. For more information, visit our website.

These Science & Innovation Theaters provide an opportunity for AMCP exhibiting companies (commercial organizations) to showcase their latest drug therapies, technologies, and a wealth of products and services affecting professionals  working in managed care pharmacy. Seating is limited and we encourage attendees to come early, as seating is on a first-come, first-seated basis. Material presented in theaters may be promotional and may concentrate on a specific product, service or therapeutic area. Therefore, these presentations are considered promotional and do not offer continuing education credit.

Wednesday, April 22

Engage the experts: Will nasal polyps blow your budget?
Provided by Optinose
6:15pm – 6:45pm / Theater #1

Description: Join us for an interactive discussion where experts debate how to handle emerging budgetary pressures in the treatment of nasal polyps.

Moderator: John Messina, PharmD is the Senior Vice President of Clinical Operation and Medical Affairs at Optinose, a Philadelphia-area based specialty pharmaceutical company focused on innovative products for patients treated by ear, nose, and throat (ENT) and allergy specialists.  Following clinical leadership roles at Cephalon and Novartis, John joined Optinose in 2010 where he has led the development and implementation of all clinical programs.

Payer Expert Panelist: Jim Kenney is founder and president of JTKENNEY, LLC a managed care pharmacy consulting practice in Waltham, Massachusetts.  Jim worked for Harvard Pilgrim Health Care for 38 years in pharmacy management, most recently as the Manager of Specialty and Pharmacy Contracts.  His work included benefit design, formulary management, pipeline monitoring, trend analysis, legislative tracking, and rebate contracting.  Jim has received national recognition for the development of value and outcomes-based contracts for pharmacy and medical products. He has experience in multiple plan designs, including: Commercial, Medicare Part D, Managed Medicaid and Health Exchanges.  During the workshop Jim will be acting as an independent consultant to Optinose.

Clinical Expert Panelist: TBD

Provided by Novartis
6:15pm – 6:45pm / Theater #
2

Title: TBD
Description: TBD
Speaker: TBD

Thursday, April 23

Interventional Innovations in Glaucoma Treatment
Provided by Allergan
12:00pm – 12:30pm / Theater #1

Description: This presentation will provide an overview of glaucoma including a discussion on current challenges in treating this disease.  Join a glaucoma specialist as he discusses:

  • Limitations in the management of Open Angle Glaucoma (OAG) & Ocular Hypertension (OHT)
  • Relationship between not achieving and maintaining target IOP and the development of visual field loss
  • Additional opportunities for Intraocular Pressure (IOP) management in patients with OAG or OHT

Speaker: Fiaz Zaman, M.D., F.A.C.S., Houston Eye Associates, Houston, Texas

Uncovering the Total Cost of Osteoporosis-Related Fractures
Provided by Allergan
12:00pm – 12:30pm / Theater #2

Description: Healthcare costs associated with osteoporosis-related fractures can impact health plans.  This presentation will uncover the direct and indirect healthcare costs among women who experienced an osteoporosis-related fracture, demonstrating that the direct economic burden associated with fractures remains high over 5 years after the fracture.  Substantial medical costs are incurred among women insured in both commercial and Medicare plans.  Evidence will be presented indicating that healthcare costs were still higher at 5 years post-fracture for commercially-insured women and for women insured in Medicare plans, compared with matched women without fracture.

Speakers: Stuart L. Silverman MD FACP FACR, Clinical Professor of Medicine, Cedars-Sinai Medical Center and UCLA School of Medicine, Medical Director, OMC Clinical Research Center and Shravanthi R Gandra, PhD, MBA, Director, Global Health Economics, Amgen, Inc.

Title: TBD
Provided by Biogen
12:45pm – 1:15pm / Theater #
1

Description: TBD

Speaker: TBD

New Perspectives on Advanced Fibrosis Due to NASH (Nonalcoholic Steatohepatitis)  
Provided by Intercept Pharmaceuticals
1:30pm – 2:00pm / Theater #
1

Description: Patients with Advanced Fibrosis due to NASH have increased liver related morbidity and mortality and may progress rapidly to cirrhosis. This presentation covers the impact of Advanced Fibrosis due to NASH, management goals and current guidelines. Also explores the role of noninvasive tests in the identification of advanced fibrosis.

Speaker: Naim Alkhouri, MD Associate Professor of Medicine, UT Health San Antonio, Director of the Metabolic Health Center, Texas Liver Institute, San Antonio, Texas

New Perspectives on Advanced Fibrosis Due to NASH (Nonalcoholic Steatohepatitis)  
Provided by RxAnte and Mosaic Pharmacy Service
1:30pm – 2:00pm / Theater #
2

Description: On behalf of MAPD plans, analytics company RxAnte partners with Mosaic Pharmacy Service to deliver long-term care pharmacy services to medically complex and vulnerable Medicare members – and so far, the results have been meaningful.

Join us for an evidence-driven review of current Mosaic programs and discussion on how plans might improve quality and financial outcomes and social determinants of health by using analytics to identify at-risk members, optimize complex medication regimens, and inform a high-touch pharmacy care model.

Speakers: Kerri Petrin, MPH, VP, Strategy and Business Development, RxAnte and Sapna Patel, RPh, Director, Clinical Services, Mosaic Pharmacy Service

Friday, April 24

Reducing the Cost of Diabetes Care Through Life-Changing Technology1,2
Provided by Abbott Diabetes Care
9:45am – 10:15am / Theater #1

Description: This session will provide a snapshot of how continuous glucose monitoring systems can improve the lives of people with diabetes. Attendees will learn about the latest international consensus recommendations for glycemic metrics, and the impact of actionable insights on optimal diabetes management. The speaker will also examine the shifting care for diabetes patients under this life-changing technology and explore how the overall cost of managing diabetes can be reduced using continuous glucose monitoring systems.

1. Fokkert M, et al. BMJ Open Diab Res Care. 2019;7(1):e000809. doi:10.1136/ bmjdrc-2019-000809

2. Quilliam BJ. Am J Manag Care 2011;17:673–80.

Speaker: Eduardo Dusty Luna, MD, Endocrinologist, RGV Adult & Geriatric Medicine Specialist

Potassium Rising – Addressing a Recurring Threat in Patients
Provided by Relypsa, Inc
9:45am – 10:15am / Theater #2

Description: Dr. Jeffrey Dunn will discuss the contemporary strategies to manage hyperkalemia, a condition that is often present in patients with chronic kidney disease (CKD). Hyperkalemia is a serious, recurrent condition that can occur quickly and unexpectedly in high-risk populations, such as patients with chronic kidney disease, heart failure and diabetes. Hyperkalemia can have serious clinical consequences such as arrhythmias, sudden death and represents a significant burden to our healthcare system due to increased emergency department visits and hospitalizations.

Speaker: Jeffrey D Dunn, PharmD, MBA, Consultant, formerly VP, Clinical Strategy and Programs and Industry Relations, Magellan RX, Salt Lake City, Utah